OneCell Diagnostics is now 1Cell.Ai
OneCell Diagnostics is now 1Cell.Ai
Next-generation liquid biopsy platform capturing live CTCs for deeper insights and more personalized cancer care.
OncoIncytes delivers a powerful alternative to traditional liquid biopsies by isolating intact, viable circulating tumor cells (CTCs) — not just circulating tumor DNA fragments. This unique approach termed Cell Biopsy®, provides clinicians and researchers with richer molecular data and true single cell resolution to detect cancer earlier, track disease progression, and inform therapy decisions with confidence.
Captures and analyzes live CTCs, not just ctDNA
Enables real-time monitoring of tumor evolution
Provides actionable insights for therapy selection and response prediction
Uncovers tumor heterogeneity at the cellular level
Seamlessly integrates into existing clinical and research workflows
A simple blood draw is used to obtain patient samples, making the process minimally invasive.
Proprietary technology isolates intact, viable circulating tumor cells from the blood.
Enables genomic, transcriptomic, and proteomic analysis of live cells, providing a dynamic picture of the tumor.
Insights guide early detection, disease monitoring, and personalized therapy decisions.
Early detection of cancer and disease recurrence
Real-time therapy response monitoring
Enhanced precision in treatment planning
Single cell based biomarker discovery
Uncovering tumor evolution and heterogeneity
Supporting drug development and clinical trials
